News & Media

Recent updates from Arcutis.

February 18, 2021

Courtney Barton Joins Arcutis as Chief Compliance Officer and Chief of Staff

February 16, 2021

Arcutis Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

February 16, 2021

Arcutis Biotherapeutics Announces Closing of Underwriters’ Over-Allotment Option in Connection with Public Offering of Common Stock

February 2, 2021

Arcutis Biotherapeutics Announces Pricing of Upsized Public Offering of Common Stock

February 1, 2021

Arcutis Biotherapeutics Announces Proposed Public Offering of Common Stock

February 1, 2021

Arcutis Announces Positive Topline Results from Pivotal DERMIS-1 and -2 Phase 3 Trials of Topical Roflumilast Cream (ARQ-151) in Plaque Psoriasis

January 20, 2021

Arcutis to Advance Topical Roflumilast Foam (ARQ-154) into Phase 3 Development for the Treatment of Seborrheic Dermatitis

January 13, 2021

Arcutis Initiates Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis

January 11, 2021

Matthew Moore Joins Arcutis as Chief Business Officer

December 21, 2020

Arcutis Biotherapeutics Added to Nasdaq Biotechnology Index

December 9, 2020

Arcutis Highlights Advanced Pipeline & Unique Immuno-Dermatology Drug Development Capabilities at Virtual Investor Day on December 9, 2020

December 7, 2020

Arcutis Announces Last Patient Completes Final Study Visit in DERMIS-1 and DERMIS-2 Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque Psoriasis

Media Resources

Corporate Fact Sheet

Uncovering Psoriasis

Journal of the American Medical Association Roflumilast Cream 0.3% Result

Media Contact

Amanda Sheldon

805.418.5006
media@arcutis.com

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download